{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T05:23:06Z","timestamp":1793856186683,"version":"4.6.1"},"reference-count":91,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Autoimmunity"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.jaut.2022.102926","type":"journal-article","created":{"date-parts":[[2022,11,3]],"date-time":"2022-11-03T02:02:04Z","timestamp":1667440924000},"page":"102926","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["Alopecia Areata: Case report and review of pathophysiology and treatment with Jak inhibitors"],"prefix":"10.1016","volume":"133","author":[{"given":"Isabelle","family":"Paggioli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy","family":"Moss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaut.2022.102926_bib1","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1038\/jid.2013.464","article-title":"Lifetime incidence risk of alopecia areata estimated at 2.1% by Rochester Epidemiology Project, 1990-2009","volume":"134","author":"Mirzoyev","year":"2014","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.jaut.2022.102926_bib2","doi-asserted-by":"crossref","first-page":"691","DOI":"10.2147\/CCID.S309215","article-title":"A comprehensive literature review of JAK inhibitors in treatment of alopecia areata","volume":"14","author":"Dillon","year":"2021","journal-title":"Clin. Cosmet. Invest. Dermatol."},{"key":"10.1016\/j.jaut.2022.102926_bib3","doi-asserted-by":"crossref","first-page":"15115","DOI":"10.1056\/NEJMra1103442","article-title":"Alopecia areata","volume":"366","author":"Gilhar","year":"2012","journal-title":"NEJM"},{"key":"10.1016\/j.jaut.2022.102926_bib4","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.jaut.2018.12.001","article-title":"Alopecia areata: a multifactorial autoimmune condition","volume":"98","author":"Simakou","year":"2019","journal-title":"J. Autoimmun."},{"issue":"3","key":"10.1016\/j.jaut.2022.102926_bib6","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1177\/1203475418824079","article-title":"The use of janus kinase inhibitors in alopecia areata: a review of the literature","volume":"23","author":"Crowley","year":"2019","journal-title":"J. Cutan. Med. Surg."},{"key":"10.1016\/j.jaut.2022.102926_bib7","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/0010-440X(91)90045-E","article-title":"Lifetime prevalence of psychiatric disorders in patients with alopecia areata","volume":"32","author":"Colon","year":"1991","journal-title":"Compr. Psychiatr."},{"key":"10.1016\/j.jaut.2022.102926_bib8","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1016\/j.jaad.2016.04.035","article-title":"Health-related quality of life (HRQol) among patients with alopecia areata (AA): a systematic review","volume":"75","author":"Liu","year":"2016","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.jaut.2022.102926_bib9","first-page":"397","article-title":"Epidemiology and burden of alopecia areata: a systematic review","volume":"8","author":"Fricke","year":"2015","journal-title":"Clin. Cosmet. Invest. Dermatol."},{"key":"10.1016\/j.jaut.2022.102926_bib10","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1056\/NEJM199908123410706","article-title":"The biology of hair follicles","volume":"341","author":"Paus","year":"1999","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jaut.2022.102926_bib11","doi-asserted-by":"crossref","first-page":"R132","DOI":"10.1016\/j.cub.2008.12.005","article-title":"The hair follicle as a dynamic miniorgan","volume":"19","author":"Schneider","year":"2009","journal-title":"Curr. Biol."},{"key":"10.1016\/j.jaut.2022.102926_bib12","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1046\/j.1365-2133.2000.03464.x","article-title":"The human hair follicle immune system: cellular composition and immune privilege","volume":"142","author":"Christoph","year":"2000","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.jaut.2022.102926_bib13","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/S0002-9440(10)63151-3","article-title":"Collapse and restoration of MHC class-1-dependent immune privilege: exploiting the human hair follicle as a model","volume":"164","author":"Ito","year":"2004","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.jaut.2022.102926_bib14","first-page":"862","article-title":"A \u2018hairy\u2019 privilege","volume":"142","author":"Paus","year":"2005","journal-title":"Trends Immunol."},{"key":"10.1016\/j.jaut.2022.102926_bib15","first-page":"1077","article-title":"Evidence that the bulge region is a site of relative immune privilege in human hair follicles","volume":"159","author":"Meyer","year":"2008","journal-title":"Br. J. Dermatol."},{"issue":"2","key":"10.1016\/j.jaut.2022.102926_bib16","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1046\/j.1087-0024.2003.00807.x","article-title":"The hair follicle and immune privilege","volume":"8","author":"Paus","year":"2003","journal-title":"J. Invest. Dermatol. Symp. Proc."},{"key":"10.1016\/j.jaut.2022.102926_bib17","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.jaad.2009.10.032","article-title":"Alopecia areata update: part 1. Clinical picture, histopathology, and pathogenesis","volume":"62","author":"Alkhalifah","year":"2010","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.jaut.2022.102926_bib18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jaad.2017.04.1141","article-title":"Alopecia areata: disease characteristics, clinical evaluation, and new perspectives on pathogenesis","volume":"78","author":"Strazzulla","year":"2018","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.jaut.2022.102926_bib19","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1038\/sj.jid.5701183","article-title":"Maintenance of hair follicle immune privilege is linked to prevention of NK cell attack","volume":"128","author":"Ito","year":"2008","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.jaut.2022.102926_bib20","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1111\/j.1365-2133.1983.tb00540.x","article-title":"Distribution of major histocompatibility antigens in normal skin","volume":"109","author":"Harrist","year":"1983","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.jaut.2022.102926_bib21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/exd.14155","article-title":"Hair follicle immune privilege and its collapse in alopecia areata","volume":"29","author":"Bertolini","year":"2020","journal-title":"Exp. Dermatol."},{"issue":"1","key":"10.1016\/j.jaut.2022.102926_bib22","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/s40257-017-0312-y","article-title":"Evaluation of the relationship between alopecia areata and viral antigen exposure","volume":"19","author":"Richardson","year":"2018","journal-title":"Am. J. Clin. Dermatol."},{"issue":"7","key":"10.1016\/j.jaut.2022.102926_bib23","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1111\/j.1468-3083.2006.02106.x","article-title":"Stress in patients with alopecia areata and vitiligo","volume":"21","author":"Manolache","year":"2007","journal-title":"J Eur Acad Dermatol veneral"},{"key":"10.1016\/j.jaut.2022.102926_bib24","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1006\/brbi.1998.0541","article-title":"Acute immobilization stress triggers skin mast cell degranulation via corticotrophin releasing hormone, neurotensin, and substance P: a link to neurogenic skin disorders","volume":"13","author":"Sing","year":"1999","journal-title":"Brain Behav. Immun."},{"key":"10.1016\/j.jaut.2022.102926_bib25","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1001\/archderm.137.1.78","article-title":"Stress and the skin","volume":"137","author":"Tausk","year":"2001","journal-title":"Arch. Dermatol."},{"key":"10.1016\/j.jaut.2022.102926_bib26","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/S0002-9440(10)63877-1","article-title":"Stress inhibits hair growth in mice by induction of premature catagen development and deleterious perifollicular inflammatory events via neuropeptide substance P-dependent pathways","volume":"162","author":"Arck","year":"2003","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.jaut.2022.102926_bib27","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1111\/exd.12209","article-title":"What causes alopecia areata?","volume":"22","author":"McElwee","year":"2013","journal-title":"Exp. Dermatol."},{"issue":"3\u20134","key":"10.1016\/j.jaut.2022.102926_bib28","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1080\/08830180902978120","article-title":"Molecular mechanisms of IFN-gamma to up-regulate MHC class I antigen processing and presentation","volume":"28","author":"Zhou","year":"2009","journal-title":"Int. Rev. Immunol."},{"issue":"5","key":"10.1016\/j.jaut.2022.102926_bib29","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1111\/bjd.16808","article-title":"Alopecia areata: a review of disease pathogenesis","volume":"179","author":"Rajabi","year":"2018","journal-title":"Br. J. Dermatol."},{"issue":"8","key":"10.1016\/j.jaut.2022.102926_bib30","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1016\/j.jid.2016.04.004","article-title":"Identification of autoantigen epitopes in alopecia areata","volume":"136","author":"Wang","year":"2016","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.jaut.2022.102926_bib31","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1056\/NEJMra1103442","article-title":"Alopecia areata","volume":"366","author":"Gilhar","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jaut.2022.102926_bib32","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.2353\/ajpath.2007.061206","article-title":"Probing the effects of stress on the human hair follicle: substance P holds central position","volume":"171","author":"Peters","year":"2007","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.jaut.2022.102926_bib33","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.it.2005.10.002","article-title":"Neuroimmunology of stress: skin takes center stage","volume":"27","author":"Paus","year":"2006","journal-title":"Trends Immunol."},{"issue":"1","key":"10.1016\/j.jaut.2022.102926_bib34","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1097\/DAD.0b013e318185a66e","article-title":"Investigation of the inflammatory mechanisms in alopecia areata","volume":"31","author":"Cetin","year":"2009","journal-title":"Am. J. Dermatopathol."},{"key":"10.1016\/j.jaut.2022.102926_bib35","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jneuroim.2003.10.041","article-title":"Critical role of mast cells in inflammatory disease and the effect of acute stress","volume":"146i","author":"Theoharides","year":"2004","journal-title":"J. Neuroimmunol."},{"issue":"2","key":"10.1016\/j.jaut.2022.102926_bib36","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1159\/000051732","article-title":"Alopecia areata and affected skin CRH receptor upregulation induced by acute emotional stress","volume":"203","author":"Katsarou-Katsari","year":"2001","journal-title":"Dermatology"},{"issue":"3","key":"10.1016\/j.jaut.2022.102926_bib37","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1152\/physrev.2000.80.3.979","article-title":"Corticotropin releasing hormone and proopiomelanocortin involvement in the cutaneous response to stress","volume":"89","author":"Slominski","year":"2000","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.jaut.2022.102926_bib38","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1111\/j.1529-8019.2011.01414.x","article-title":"Histopathology of alopecia areata, acute and chronic: why is it important to the clinician?","volume":"24","author":"Dy","year":"2011","journal-title":"Dermatol. Ther."},{"key":"10.1016\/j.jaut.2022.102926_bib39","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1001\/archderm.139.12.1555","article-title":"Histopathologic features of alopecia areata: a new look","volume":"139","author":"Whiting","year":"2003","journal-title":"Arch. Dermatol."},{"key":"10.1016\/j.jaut.2022.102926_bib40","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1046\/j.1365-2133.1996.d01-1099.x","article-title":"Effects of interleukins, colony-stimulating factor and tumor necrosis factor-a in alopecia areata","volume":"135","author":"Philpott","year":"1996","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.jaut.2022.102926_bib41","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1007\/s004030050209","article-title":"Lesional alopecia areata T lymphocytes downregulate epithelial cell proliferation","volume":"289","author":"Thein","year":"1997","journal-title":"Arch. Dermatol. Res."},{"issue":"7","key":"10.1016\/j.jaut.2022.102926_bib42","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1093\/intimm\/dxz039","article-title":"Pathomechanisms of immune-mediated alopecia","volume":"31","author":"Anzai","year":"2019","journal-title":"Int. Immunol."},{"key":"10.1016\/j.jaut.2022.102926_bib43","doi-asserted-by":"crossref","first-page":"2152","DOI":"10.2353\/ajpath.2010.100454","article-title":"The pathogenesis of primary cicatricial alopecias","volume":"177","author":"Harris","year":"2010","journal-title":"Am. J. Pathol."},{"issue":"3","key":"10.1016\/j.jaut.2022.102926_bib44","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/j.jaad.2011.02.017","article-title":"Histologic features of alopecia areata other than peribulbar lymphocytic infiltrates","volume":"65","author":"Peckham","year":"2011","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.jaut.2022.102926_bib45","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/S0190-9622(97)70219-6","article-title":"Eosinophils in fibrous tracts and near hair bulbs: a helpful diagnostic feature of AA","volume":"37","author":"Elston","year":"1997","journal-title":"J. Am. Acad. Dermatol."},{"issue":"6","key":"10.1016\/j.jaut.2022.102926_bib46","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1590\/S0365-05962012000600010","article-title":"Clinical and histological challenge in the differential diagnosis of diffuse alopecia: female androgenetic alopecia, telogen effluvium and alopecia areata-Part II","volume":"87","author":"Werner","year":"2012","journal-title":"An. Bras. Dermatol."},{"issue":"3","key":"10.1016\/j.jaut.2022.102926_bib47","article-title":"Alopecia areata","volume":"16","author":"Pratt","year":"2017","journal-title":"Nat. Rev. Dis. Prim."},{"issue":"4","key":"10.1016\/j.jaut.2022.102926_bib48","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/j.jaad.2005.12.007","article-title":"Familial aggregation of alopecia areata","volume":"54","author":"Blaumeiser","year":"2006","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.jaut.2022.102926_bib49","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1038\/nri1805","article-title":"MHC class II proteins and disease: a structural perspective","volume":"6","author":"Jones","year":"2006","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.jaut.2022.102926_bib50","doi-asserted-by":"crossref","first-page":"5966","DOI":"10.1038\/ncomms6966","article-title":"Genome-wide meta-analysis in alopecia areata resolves HLA associations and reveals two new susceptibility loci","volume":"6","author":"Betz","year":"2015","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jaut.2022.102926_bib51","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1038\/JID.2015.402","article-title":"Functional interpretation of genome-wide association study in alopecia areata","volume":"136","author":"Petukhova","year":"2016","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.jaut.2022.102926_bib52","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1007\/s00251-013-0703-z","article-title":"Association analysis of the HLA-C gene in Japanese alopecia areata","volume":"65","author":"Haida","year":"2013","journal-title":"Immunogenetics"},{"key":"10.1016\/j.jaut.2022.102926_bib53","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1001\/archderm.1986.01660140070020","article-title":"Topical minoxidil dose-response effect in alopecia areata","volume":"122","author":"Fiedler-Weiss","year":"1986","journal-title":"Arch. Dermatol."},{"key":"10.1016\/j.jaut.2022.102926_bib54","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1001\/archderm.1987.01660350088019","article-title":"Evaluation of oral minoxidil in the treatment of alopecia areata","volume":"123","author":"Fiedler-Weiss","year":"1987","journal-title":"Arch. Dermatol."},{"key":"10.1016\/j.jaut.2022.102926_bib55","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1111\/ajd.12941","article-title":"Treatment of alopecia areata: an Australian expert consensus statement","volume":"60","author":"Cranwell","year":"2019","journal-title":"Australas. J. Dermatol."},{"key":"10.1016\/j.jaut.2022.102926_bib56","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1038\/ni.1701","article-title":"Selectivity and therapeutic inhibition of kinases: to be or not to be?","volume":"10","author":"Ghoreschi","year":"2009","journal-title":"Nat. Immunol."},{"issue":"9","key":"10.1016\/j.jaut.2022.102926_bib57","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1016\/j.jid.2018.05.027","article-title":"Montagna symposium 2017-janus kinase inhibitors for treatment of alopecia areata","volume":"138","author":"Wang","year":"2018","journal-title":"J. Invest. Dermatol."},{"issue":"1","key":"10.1016\/j.jaut.2022.102926_bib58","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1111\/bcpt.12164","article-title":"Therapeutic targeting of the JAK\/STAT pathway","volume":"114","author":"Aittomaki","year":"2013","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"key":"10.1016\/j.jaut.2022.102926_bib59","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1007\/s40265-017-0701-9","article-title":"JAK-STAT signaling as a target for inflammatory and autoimmune diseases: current and future prospects","volume":"77","author":"Banerjee","year":"2017","journal-title":"Drugs"},{"issue":"4","key":"10.1016\/j.jaut.2022.102926_bib60","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1016\/j.jaad.2016.12.005","article-title":"JAK inhibitors in dermatology: the promise of a new drug class","volume":"76","author":"Damsky","year":"2017","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.jaut.2022.102926_bib61","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1146\/annurev-med-051113-024537","article-title":"The JAK-STAT pathway: impact on human disease and therapeutic intervention","volume":"66","author":"O'Shea","year":"2015","journal-title":"Annu. Rev. Med."},{"issue":"1","key":"10.1016\/j.jaut.2022.102926_bib62","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/nrrheum.2015.167","article-title":"Type I\/II cytokines, JAKs and new strategies for treating autoimmune diseases","volume":"12","author":"Schwartz","year":"2016","journal-title":"Nat. Rev. Rheumatol."},{"issue":"12","key":"10.1016\/j.jaut.2022.102926_bib63","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1038\/nrd.2017.201","article-title":"JAK inhibition as a therapeutic strategy for immune and inflammatory diseases","volume":"16","author":"Schwartz","year":"2017","journal-title":"Nat. Rev. Drug Discov."},{"issue":"3","key":"10.1016\/j.jaut.2022.102926_bib64","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1038\/ng1097","article-title":"Impaired response to interferon-alpha\/beta and lethal viral disease in human STAT1 deficiency","volume":"33","author":"Dupuis","year":"2003","journal-title":"Nat. Genet."},{"key":"10.1016\/j.jaut.2022.102926_bib65","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1016\/j.immuni.2019.03.028","article-title":"The gamma chain family of cytokines: basic biology to therapeutic ramifications","volume":"50","author":"Leonard","year":"2019","journal-title":"Immunity"},{"issue":"6","key":"10.1016\/j.jaut.2022.102926_bib66","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1038\/ni.2030","article-title":"Modulation of cytokine receptors by IL-2 broadly regulates differentiation into helper T cell lineages","volume":"12","author":"Liao","year":"2011","journal-title":"Nat. Immunol."},{"issue":"14","key":"10.1016\/j.jaut.2022.102926_bib67","doi-asserted-by":"crossref","first-page":"1866","DOI":"10.1126\/sciadv.abd1866","article-title":"Blockade of IL-7 signaling suppresses inflammatory responses and reverses alopecia areata in C3H\/Hel mice","volume":"7","author":"Dai","year":"2021","journal-title":"Sci. Adv."},{"issue":"11","key":"10.1016\/j.jaut.2022.102926_bib68","doi-asserted-by":"crossref","first-page":"6031","DOI":"10.4049\/jimmunol.154.11.6031","article-title":"IFN-gamma dependent IL-7 gene regulation in keratinocytes","volume":"154","author":"Ariizumi","year":"1995","journal-title":"J. Immunol."},{"issue":"9","key":"10.1016\/j.jaut.2022.102926_bib69","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1038\/nm.3645","article-title":"Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition","volume":"20","author":"Xing","year":"2014","journal-title":"Nat. Med."},{"key":"10.1016\/j.jaut.2022.102926_bib70","doi-asserted-by":"crossref","first-page":"2323","DOI":"10.2147\/DDDT.S172638","article-title":"Role of janus kinase inhibitors in the treatment of alopecia areata","volume":"12","author":"Triyangkulsri","year":"2018","journal-title":"Drug Des. Dev. Ther."},{"issue":"9","key":"10.1016\/j.jaut.2022.102926_bib71","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1038\/nm.3645","article-title":"Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by jak inhibition","volume":"20","author":"Xing","year":"2014","journal-title":"Nat. Med."},{"key":"10.1016\/j.jaut.2022.102926_bib72","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1007\/s12325-017-0542-7","article-title":"The changing landscape of alopecia areata: the therapeutic paradigm","volume":"34","author":"Renart Yuval","year":"2017","journal-title":"Adv. Ther."},{"issue":"7","key":"10.1016\/j.jaut.2022.102926_bib73","first-page":"1","article-title":"Selective inhibition of JAK3 signaling is sufficient to reverse alopecia areata","volume":"6","author":"Zhenpeng","year":"2021","journal-title":"JCI Insight"},{"issue":"19","key":"10.1016\/j.jaut.2022.102926_bib74","doi-asserted-by":"crossref","first-page":"4617","DOI":"10.1016\/j.bmcl.2014.08.046","article-title":"Selective inhibitors of the janus kinase Jak3-are they effective?","volume":"24","author":"Thoma","year":"2014","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"2","key":"10.1016\/j.jaut.2022.102926_bib75","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1124\/jpet.116.239723","article-title":"Evaluation of JAK3 biology in autoimmune disease using a highly selective, irreversible JAK3 inhibitor","volume":"361","author":"Elwood","year":"2017","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.jaut.2022.102926_bib76","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.jaad.2016.09.006","article-title":"Tofactinib for the treatment of alopecia areata and variants in adolescents","volume":"76","author":"Craiglow","year":"2017","journal-title":"J. Am. Acad. Dermatol."},{"issue":"15","key":"10.1016\/j.jaut.2022.102926_bib77","article-title":"Safety and efficacy of the JAK inhibitor tofacitinib citrate in patients with alopecia areata","volume":"1","author":"Crispin","year":"2016","journal-title":"JCI Insight"},{"issue":"7","key":"10.1016\/j.jaut.2022.102926_bib78","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1016\/j.jid.2018.01.032","article-title":"An open-label pilot study to evaluate the efficacy of tofacitinib in moderate to severe patch type Alopecia areata, totalis and Universalis","volume":"138","author":"Jabbari","year":"2018","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.jaut.2022.102926_bib79","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.jaad.2016.09.007","article-title":"Tofacitinib for the treatment of severe alopecia areata and variants: a study of 90 patients","volume":"76","author":"Liu","year":"2017","journal-title":"J. Am. Acad. Dermatol."},{"issue":"6","key":"10.1016\/j.jaut.2022.102926_bib80","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1001\/jamadermatol.2017.0001","article-title":"Treatment of alopecia areata with tofacitinib","volume":"153","author":"Ibrahim","year":"2017","journal-title":"JAMA Dermatol"},{"issue":"6","key":"10.1016\/j.jaut.2022.102926_bib81","first-page":"12","article-title":"Long-term treatment with tofacitinib in severe alopecia areata: an update","volume":"12","author":"Hogan","year":"2019","journal-title":"J. Clin. Aesthet. Dermatol."},{"issue":"7","key":"10.1016\/j.jaut.2022.102926_bib82","first-page":"800","article-title":"Successful treatment of severe alopecia areata with oral or topical tofacitinib","volume":"17","author":"Cheng","year":"2018","journal-title":"J. Drugs Dermatol. JDD"},{"key":"10.1016\/j.jaut.2022.102926_bib83","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1111\/jdv.15937","article-title":"Benefit and risk profile of tofacitinib for the treatment of alopecia areata: a systemic review and meta-analysis","volume":"34","author":"Guo","year":"2020","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"issue":"5","key":"10.1016\/j.jaut.2022.102926_bib84","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1016\/j.jaad.2017.06.027","article-title":"Oral tofacitinib monotherapy in Korean patients with refractory moderate-to-severe alopecia areata: a case series","volume":"77","author":"Park","year":"2017","journal-title":"J. Am. Acad. Dermatol."},{"issue":"3","key":"10.1016\/j.jaut.2022.102926_bib85","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/j.jaad.2019.08.080","article-title":"Combination tofacitinib and oral minoxidil treatment for severe alopecia areata","volume":"85","author":"Wambier","year":"2019","journal-title":"J. Am. Acad. Dermatol."},{"issue":"5","key":"10.1016\/j.jaut.2022.102926_bib86","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1111\/jdv.15489","article-title":"JAK inhibitors for alopecia areata: a systematic review and meta-analysis","volume":"33","author":"Phan","year":"2019","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"10.1016\/j.jaut.2022.102926_bib87","series-title":"An Atlas of Hair Pathology with Clinical Correlations","author":"Sperling","year":"2003"},{"key":"10.1016\/j.jaut.2022.102926_bib88","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1097\/00000372-200606000-00051","article-title":"Histopathologic evaluation of alopecias","volume":"28","author":"Sellheyer","year":"2006","journal-title":"Am. J. Dermatopathol."},{"key":"10.1016\/j.jaut.2022.102926_bib89","doi-asserted-by":"crossref","first-page":"837","DOI":"10.3899\/jrheum.130683","article-title":"Safety and efficacy of tofacitinib, an oral Janus kinase inhibitor, for the treatment of rheumatoid arthritis in open-label, long-term extension studies","volume":"41","author":"Wollenhaupt","year":"2014","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.jaut.2022.102926_bib90","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1056\/NEJMoa1109071","article-title":"Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis","volume":"37","author":"Fleischmann","year":"2012","journal-title":"N. Engl. J. Med."},{"issue":"18","key":"10.1016\/j.jaut.2022.102926_bib92","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1056\/NEJMoa2110343","article-title":"Two phase 3 trials of baricitinib for alopecia areata","volume":"386","author":"King","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jaut.2022.102926_bib93","unstructured":"A phase 3 study to evaluate the efficacy and safety of CTP-543 in adult patients with moderate to severe alopecia areata. THRIVE-AA1 and THRIVE-AA2. https:\/\/clinicaltrials.gov."}],"container-title":["Journal of Autoimmunity"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0896841122001342?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0896841122001342?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T08:33:15Z","timestamp":1760257995000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0896841122001342"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":91,"alternative-id":["S0896841122001342"],"URL":"https:\/\/doi.org\/10.1016\/j.jaut.2022.102926","relation":{},"ISSN":["0896-8411"],"issn-type":[{"value":"0896-8411","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Alopecia Areata: Case report and review of pathophysiology and treatment with Jak inhibitors","name":"articletitle","label":"Article Title"},{"value":"Journal of Autoimmunity","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaut.2022.102926","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"102926"}}